Dozens of police teams across Germany raided homes before dawn in a coordinated crackdown on a recent Tuesday. The state police weren't looking for drugs or guns, they were looking for people ...

Germany’s political system is set up to exclude extremists. Yet the country is waking up to a new political reality that has lurched to the right with the once outcast Alternative for Germany ...

The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).

In Germany, gross domestic product grew 0.1% in ... Labor and Welfare has approved an extension of the indication of Arexvy to prevent respiratory syncytial virus disease to include adults aged ...

GSK has counted the cost of narrower US recommendations on the use of RSV vaccines, which caused a 51% decline in sales of its Arexvy shot in 2024, but still managed to post reasonable sales ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

Much credit goes to Arexvy, GSK’s first-on-the-market RSV vaccine, which was a triumph for GSK after the company failed to develop a COVID jab. Arexvy generated $1.6 billion in sales in its ...

Vaccine sales fell 14% to £2.21B, with Arexvy sales down 70%, while Specialty Medicines grew 14% to £3.29B, and HIV drug revenue rose. Our government trade tracker caught Pelosi’s 169% AI winner.

The Therapeutic Goods Administration (TGA) has approved AREXVY to be used as a RSV vaccine for Australians aged 60 and over.